• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[동아사이언스] [재생의료 최전선]② 기적의 항암제 ‘CAR-T’ 한계 극복 도전하는 토종기업

2025/05/30

[재생의료 최전선]② 기적의 항암제 ‘CAR-T’ 한계 극복 도전하는 토종기업 : 동아사이언스

Prev[비즈월드] [국내 CAR-T 선두 큐로셀 ②] “‘림카토’ 넘어 더 다양한 암종 정복으로”
Next큐로셀, BIO USA 2025 기업 발표자로 선정…글로벌 파트너십 본격 확대
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.